Pharmaceutical and beauty sectors show divergent M&A trends

Mergers and acquisitions in the pharmaceutical and beauty industries are following contrasting patterns. In the life sciences sector, companies are executing fewer deals compared to previous years, but the total value and median size of transactions have risen significantly. This trend is driven by an increasing selectivity among buyers and the urgent need to replenish pipelines ahead of looming patent expirations. Large pharmaceutical firms are utilizing substantial cash flows to acquire later-stage drugs or established platforms to replace revenue lost to patent cliffs.

Conversely, the beauty industry is experiencing a rise in deal volume but a decline in average transaction value. While deal activity grew in 2025, the median deal value dropped from $26 million to $22 million. Market activity is currently dominated by small transactions—those below $100 million—which accounted for 77 percent of deals in 2025 and 86 percent in the first half of 2026. Buyers are favoring small or mega brands, while midsize brands have struggled to find buyers. Private equity is increasingly active in this space as large conglomerates restructure their portfolios.